Ibandronic Acid

Summary

Ibandronic Acid (CHEMBL997) is an approved small molecule (ATC M05BA06) targeting FDPS and FDFT1; indicated across 11 conditions including postmenopausal osteoporosis and osteoporosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M05BA06
• Targets: 2 (FDPS, FDFT1)
• Indications: 11 conditions
• Clinical trials: 52
• Chemistry: 319.23 Da · C9H23NO7P2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL997
Name	Ibandronic Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	60852
ATC	M05BA06
Molecular formula	C9H23NO7P2
Molecular weight	319.23
InChIKey	MPBVHIBUJCELCL-UHFFFAOYSA-N

SMILES: CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O

IUPAC name: [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid

Also known as: Acide ibandronique, Acido ibandronico, Bondenza, Ibandronate, Ibandronic acid, NSC-722623, ibandronate, Ibandronic Acid, SID90340689, ACIDE_IBANDRONIQUE, ACIDE_ICADRONIQUE, IBANDRONIC ACID

Parent form; salt/anhydrous children: CHEMBL1201008, CHEMBL3989569

Patent coverage: 11,382 distinct patent families (48,864 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
FDPS	farnesyl diphosphate synthase	Inhibition	6.71	72.4%	P14324
FDFT1	squalene synthase	Inhibition	6.19	10%	P37268

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Farnesyl pyrophosphate synthase, Type-1 angiotensin II receptor, Mu-type opioid receptor, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, Squalene synthase, Geranylgeranyl pyrophosphate synthase.

Bioactivity

ChEMBL activities: 13 potent at pChembl ≥ 5 of 16 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FDPS	8.44	Ki	3.6	nM	CHEMBL_ACT_2155089
FDPS	7.7	IC50	20	nM	CHEMBL_ACT_24973376
FDPS	7.7	IC50	20	nM	CHEMBL_ACT_875902
FDPS	7.59	IC50	25.4	nM	CHEMBL_ACT_2155088
FDPS	7.34	Ki	46	nM	CHEMBL_ACT_1070849
FDPS	6.71	Ki	195	nM	CHEMBL_ACT_2155045
FDPS	6.32	IC50	480	nM	CHEMBL_ACT_1070848
FDPS	6.32	IC50	478.6	nM	CHEMBL_ACT_1070850
Q02769	6.19	IC50	640	nM	CHEMBL_ACT_3256113
FDPS	5.98	IC50	1052	nM	CHEMBL_ACT_2155044
PDE3A	5.72	AC50	1900	nM	CHEMBL_ACT_25191113
AGTR1	5.21	AC50	6200	nM	CHEMBL_ACT_25177385
OPRM1	5.07	AC50	8500	nM	CHEMBL_ACT_25147173

Target pathways

Aggregated over 2 target gene(s): FDPS, FDFT1.

Top Reactome pathways

4 total, by targets touching each:

Pathway	Targets	Genes
Cholesterol biosynthesis	2	FDFT1, FDPS
Activation of gene expression by SREBF (SREBP)	2	FDFT1, FDPS
Lanosterol biosynthesis	2	FDFT1, FDPS
PPARA activates gene expression	1	FDFT1

Dominant GO biological processes

GO term	Targets
cholesterol biosynthetic process	2
lipid metabolic process	2
steroid biosynthetic process	2
steroid metabolic process	2
cholesterol metabolic process	2
sterol biosynthetic process	2
geranyl diphosphate biosynthetic process	1
trans, trans-farnesyl diphosphate biosynthetic process	1
isoprenoid biosynthetic process	1
farnesyl diphosphate metabolic process	1
lipid biosynthetic process	1
hexose transmembrane transport	1
biosynthetic process	1

Indications & clinical

Indications

11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
postmenopausal osteoporosis	3	MONDO:0008159	EFO:0003854
osteoporosis	3	MONDO:0005298	EFO:0003882
bone disorder	3	MONDO:0005381	EFO:0004260
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
osteonecrosis	3	MONDO:0005380	EFO:0004259
lymphoid neoplasm	3	MONDO:0005157	EFO:0001642
bone neoplasm	3	MONDO:0019060	EFO:0003820
breast neoplasm	3	MONDO:0021100	MONDO:0007254

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 52.

Phase distribution

Phase	Trials
PHASE4	18
PHASE3	17
PHASE2	8
Not specified	6
PHASE2/PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00148915	PHASE4	COMPLETED	A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo
NCT00327990	PHASE4	COMPLETED	Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate
NCT00405392	PHASE4	COMPLETED	Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis
NCT00446589	PHASE4	TERMINATED	The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density
NCT00492843	PHASE4	TERMINATED	Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis
NCT00545051	PHASE4	COMPLETED	A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
NCT00545363	PHASE4	COMPLETED	A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)
NCT00662077	PHASE4	WITHDRAWN	Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort
NCT00668330	PHASE4	COMPLETED	Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus
NCT01287533	PHASE4	COMPLETED	Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids
NCT02156999	PHASE4	UNKNOWN	Changes of Bone Turnover Markers and Bone Mineral Density After Osteoporosis Treatment
NCT02553707	PHASE4	COMPLETED	A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer
NCT02564107	PHASE4	COMPLETED	A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease
NCT02598440	PHASE4	COMPLETED	A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
NCT02598453	PHASE4	COMPLETED	PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
NCT02598934	PHASE4	COMPLETED	A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis
NCT02604836	PHASE4	COMPLETED	A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
NCT02948881	PHASE4	COMPLETED	A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo
NCT00082927	PHASE3	COMPLETED	Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain
NCT00092053	PHASE3	COMPLETED	Study of Investigational Drug in Osteoporosis (MK-0217-908)
NCT00099177	PHASE3	TERMINATED	A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
NCT00099203	PHASE3	TERMINATED	A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
NCT00127205	PHASE3	COMPLETED	S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
NCT00196859	PHASE3	COMPLETED	Study in Elderly Patients With Early Breast Cancer (ICE)
NCT00301886	PHASE3	WITHDRAWN	S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
NCT00326820	PHASE3	UNKNOWN	Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
NCT00397839	PHASE3	COMPLETED	The Effect Of Oral Ibandronate In Male Osteoporosis
NCT00423384	PHASE2/PHASE3	UNKNOWN	Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.
NCT00447915	PHASE3	COMPLETED	Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis
NCT00545779	PHASE3	COMPLETED	BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
NCT00683163	PHASE2/PHASE3	COMPLETED	PTH & Ibandronate Combination Study (PICS)
NCT00824993	PHASE3	COMPLETED	Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
NCT00936897	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
NCT02114489	PHASE3	TERMINATED	Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis
NCT02561039	PHASE3	COMPLETED	A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
NCT02716792	PHASE3	COMPLETED	A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer
NCT02739594	PHASE3	TERMINATED	Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
NCT00381368	PHASE2	UNKNOWN	Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients
NCT00478270	PHASE2	WITHDRAWN	A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.
NCT00502736	PHASE2	COMPLETED	A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

14 molecules share ≥1 primary target. Top 14 by shared-target count:

Molecule	Source	Status	Shared targets
ALENDRONIC ACID	ChEMBL + PubChem	Phase 4 (approved)	FDPS
AMIODARONE	ChEMBL + PubChem	Phase 4 (approved)	FDFT1
PAMIDRONIC ACID	ChEMBL + PubChem	Phase 4 (approved)	FDPS
RISEDRONIC ACID	ChEMBL + PubChem	Phase 4 (approved)	FDPS
ZOLEDRONIC ACID	ChEMBL + PubChem	Phase 4 (approved)	FDPS
ALENDRONATE	ChEMBL	Phase 4 (approved)	FDPS
MINODRONIC ACID	ChEMBL	Phase 4 (approved)	FDPS
LAPAQUISTAT	ChEMBL	Phase 3	FDFT1
NERIDRONIC ACID	ChEMBL	Phase 3	FDPS
PYROPHOSPHORIC ACID	ChEMBL + PubChem	Phase 2 (approved)	FDPS
INCADRONIC ACID	ChEMBL	Phase 2	FDPS
PIRIDRONIC ACID	ChEMBL	Phase 2	FDPS
SQ109	ChEMBL	Phase 2	FDFT1
Lovastatin	PubChem	Approved	FDPS